Ngam Advisors LP Has Boosted Myriad Genetics (MYGN) Holding By $359,375; Global Power Equipment Group (GLPW) Has 0.5 Sentiment

November 15, 2017 - By Michael Collier

Global Power Equipment Group Inc (GLPW) investors sentiment decreased to 0.5 in Q2 2017. It’s down -2.50, from 3 in 2017Q1. The ratio has worsened, as 1 funds increased and opened new positions, while 2 sold and reduced their holdings in Global Power Equipment Group Inc. The funds in our database reported: 4.65 million shares, down from 4.76 million shares in 2017Q1. Also, the number of funds holding Global Power Equipment Group Inc in top ten positions decreased from 1 to 0 for a decrease of 1. Sold All: 1 Reduced: 1 Increased: 1 New Position: 0.

Ngam Advisors Lp increased Myriad Genetics (MYGN) stake by 15.15% reported in 2017Q2 SEC filing. Ngam Advisors Lp acquired 14,375 shares as Myriad Genetics (MYGN)’s stock rose 13.21%. The Ngam Advisors Lp holds 109,275 shares with $2.82 million value, up from 94,900 last quarter. Myriad Genetics now has $2.17 billion valuation. The stock decreased 3.42% or $1.11 during the last trading session, reaching $31.36. About shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 37.47% since November 15, 2016 and is downtrending. It has underperformed by 54.17% the S&P500.

Wynnefield Capital Inc holds 3.64% of its portfolio in Global Power Equipment Group Inc for 3.17 million shares. Adirondack Research & Management Inc. owns 664,598 shares or 0.89% of their US portfolio. Moreover, Rutabaga Capital Management Llc Ma has 0.34% invested in the company for 528,491 shares. The New York-based Walthausen & Co. Llc has invested 0.09% in the stock. Edge Wealth Management Llc, a New York-based fund reported 30,000 shares.

The stock increased 1.28% or $0.05 on November 14, reaching $3.95. About 800 shares traded. Global Power Equipment Group Inc (GLPW) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Global Power Equipment Group Inc. is a design, engineering and manufacturing firm providing an array of equipment and services to the global power infrastructure, energy and process industries. The company has market cap of $70.23 million. The Products segment includes two primary product categories: Electrical Solutions, which provides custom-configured electrical houses and generator enclosures for various industries. It currently has negative earnings. The Services segment provides lifecycle maintenance, repair, on-site specialty support, outage management, construction and fabrication services for the power generation, industrial, chemical/petrochemical processing, and gas and oil industries.

Among 19 analysts covering Myriad Genetics (NASDAQ:MYGN), 2 have Buy rating, 4 Sell and 13 Hold. Therefore 11% are positive. Myriad Genetics has $52 highest and $15 lowest target. $32.53’s average target is 3.73% above currents $31.36 stock price. Myriad Genetics had 48 analyst reports since July 21, 2015 according to SRatingsIntel. On Tuesday, July 21 the stock rating was initiated by Gabelli with “Buy”. The firm has “Market Perform” rating given on Wednesday, August 10 by Wells Fargo. The firm has “Underperform” rating by Bank of America given on Friday, July 29. The company was maintained on Wednesday, August 10 by Morgan Stanley. The firm has “Market Perform” rating given on Tuesday, August 25 by Wells Fargo. The rating was maintained by Leerink Swann with “Market Perform” on Wednesday, May 4. The stock has “Neutral” rating by Goldman Sachs on Tuesday, December 8. The company was maintained on Tuesday, September 12 by Jefferies. Deutsche Bank initiated the stock with “Buy” rating in Thursday, January 7 report. As per Tuesday, September 15, the company rating was maintained by Mizuho.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.